Research and Development

Tacking the World's
Unmet Medical Needs
with Innovative R&D

Through R&D, we are continuously creating life-changing value with unrivaled competitive advantage through our strengths in technology and disease-oriented research and development, and open innovation actively incorporating external expertise.
Being efficient, agile & fast, we are driving these efforts forward to deliver this value to people living with conditions around the world.

CMO Message

We don’t just make medicine,
we make people smile.

By integrating our “disease science” which aims to gain a deep understanding of diseases and identify new avenues for treatment, with our “drug discovery technology” which leverages these avenues into optimal solutions, we are driving the creation of world-class innovative drugs in collaboration with external partners.
Kyowa Kirin may not be a large company, but we are united in our commitment to make people smile. Today and at this moment, we remain dedicated to the research and development of innovative new drugs.

Director of the Board, Executive Vice President Chief Medical Officer (CMO)

Takeyoshi Yamashita, Ph.D.

STORY FOR VISION 2030R&D Strategy

CREATING AND DELIVERING
LIFE-CHANGING VALUE

Disease Science

We focus on three disease areas, strategically concentrating our in-house resources and conducting patient-centric drug discovery research.

Focus disease areas

  • Bone &
    mineral

  • Intractable
    hematological
    diseases/
    Hemato oncology

  • Rare diseases

For more information

Drug Discovery
Technology

We are amid the development of bio/antibody technology and build platforms to create breakthrough new drugs by making full use of various modalities.

Key modalities

  • Advanced therapeutic
    antibodies

  • Hematopoietic stem cell
    gene therapy

For more information

Partnerships

We welcome partnerships and relationships with pharma, biotech, academia to help each other grows and drive competitive drug discovery to help patients, faster.

Creating synergies through collaboration

  • Open innovation

  • Strategic partnerships

For more information
Disease Science / Focus disease areas: bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases Explore UMN, causes and mechanisms of disease in depth Pursuit of molecular and cellular regulatory mechanisms for therapeutic realization Drug Discovery Technology / Strengthening Innovative Modalities: Advanced Antibody Technologies, Hematopoietic stem cell gene therapy Application of optimal modalities for therapeutic realization Evolution of drug discovery methods through AI and data science External Collaboration / Open Innovation Partnering→Life-changing Value Creation → Assets in focus disease areas / Strategic Partnering Assets
  • *
    Assets outside of the disease areas of focus are designated as strategic partnering assets, and value maximization is achieved through collaboration with partners.

R&D STORIES

See more

DEVELOPMENT
PIPELINE

Click to see the up-to-date list of new drug candidates that Kyowa Kirin is developing with its cutting-edge technologies.

For more information
  • phase 1 9
  • phase 2 5
  • phase 3 4

In total 18 Programs

PRODUCTION AND QUALITY ASSURANCE

We cultivate human capital with a global outlook and advanced expertise,
while maintaining facilities and systems that comply with GMP,
the international standard for pharmaceutical manufacturing and quality control.
By consistently delivering reliable, high-quality pharmaceuticals, we bring smiles to patients around the world.

For more information

R&D STRUCTURE

  • Drug Discovery Process

    Kyowa Kirin’s drug discovery is divided into eight processes to maximize the integration of all technologies, knowledge, and know-how from research and development to manufacturing.

    For more information

  • Global R&D Structure

    Our Research and Development functions collaborate closely to advance global drug discovery initiatives.
    This section introduces our collaborative structure from a global perspective.

    For more information

Research & Development

What we do

R&D Structure